Compounders Research Compare

Aprea Therapeutics, Inc.(APRE)

Biotechnology · Boston, PA

$0.64-0.04 (-5.94%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Boston, PA

8 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Oren Gilad

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T22:40:36.241Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:40:36.241Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 7,869,254
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 41,233,428
TTM free cash flow · period ending 2026-06-30: -12,183,411

FMP input reference: d88ebff11657cb0645ea93f74423bc241bf41286751ec96f31399ab1bd3406dc

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

APRE EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

APRE Competitors' EV/FCF Ratio

Aprea Therapeutics, Inc.

Current

Market Cap

$7.87M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Traws Pharma, Inc.

Market Cap

$7.92M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CNS Pharmaceuticals, Inc.

Market Cap

$7.75M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GT Biopharma, Inc.

Market Cap

$8.04M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DataMEDS AI, Inc.

Market Cap

$8.05M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ENDRA Life Sciences Inc.

Market Cap

$7.67M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Mangoceuticals, Inc.

Market Cap

$7.64M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HeartSciences Inc.

Market Cap

$8.14M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Quince Therapeutics, Inc.

Market Cap

$7.46M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Healthcare Triangle, Inc.

Market Cap

$8.33M

EV/FCF Ratio

N/A

TTM Avg

12.59x

3Y Avg

12.59x

5Y Avg

12.59x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Aprea Therapeutics, Inc. (APRE)	$7.87M	N/A	N/A	N/A	N/A
Traws Pharma, Inc. (TRAW)vs ›	$7.92M	N/A	N/A	N/A	N/A
CNS Pharmaceuticals, Inc. (CNSP)vs ›	$7.75M	N/A	N/A	N/A	N/A
GT Biopharma, Inc. (GTBP)vs ›	$8.04M	N/A	N/A	N/A	N/A
DataMEDS AI, Inc. (MEDS)vs ›	$8.05M	N/A	N/A	N/A	N/A
ENDRA Life Sciences Inc. (NDRA)vs ›	$7.67M	N/A	N/A	N/A	N/A
Mangoceuticals, Inc. (MGRX)vs ›	$7.64M	N/A	N/A	N/A	N/A
HeartSciences Inc. (HSCS)vs ›	$8.14M	N/A	N/A	N/A	N/A
Quince Therapeutics, Inc. (QNCX)vs ›	$7.46M	N/A	N/A	N/A	N/A
Healthcare Triangle, Inc. (HCTI)vs ›	$8.33M	N/A	12.59x	12.59x	12.59x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics